348 related articles for article (PubMed ID: 11873938)
1. Catechol-O-methyltransferase and Parkinson's disease.
Tai CH; Wu RM
Acta Med Okayama; 2002 Feb; 56(1):1-6. PubMed ID: 11873938
[TBL] [Abstract][Full Text] [Related]
2. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
[TBL] [Abstract][Full Text] [Related]
3. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.
Bonifácio MJ; Palma PN; Almeida L; Soares-da-Silva P
CNS Drug Rev; 2007; 13(3):352-79. PubMed ID: 17894650
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.
Kaakkola S
Drugs; 2000 Jun; 59(6):1233-50. PubMed ID: 10882160
[TBL] [Abstract][Full Text] [Related]
5. Extending levodopa action: COMT inhibition.
Martínez-Martín P; O'Brien CF
Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
[TBL] [Abstract][Full Text] [Related]
6. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.
Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR
Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397
[TBL] [Abstract][Full Text] [Related]
7. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.
Bialecka M; Kurzawski M; Klodowska-Duda G; Opala G; Tan EK; Drozdzik M
Pharmacogenet Genomics; 2008 Sep; 18(9):815-21. PubMed ID: 18698234
[TBL] [Abstract][Full Text] [Related]
8. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
Müller T
Drugs; 2015 Feb; 75(2):157-74. PubMed ID: 25559423
[TBL] [Abstract][Full Text] [Related]
9. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.
Bonifati V; Meco G
Pharmacol Ther; 1999 Jan; 81(1):1-36. PubMed ID: 10051176
[TBL] [Abstract][Full Text] [Related]
10. Influence of COMT inhibition on levodopa pharmacology and therapy.
Goetz CG
Neurology; 1998 May; 50(5 Suppl 5):S26-30. PubMed ID: 9591519
[TBL] [Abstract][Full Text] [Related]
11. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
[TBL] [Abstract][Full Text] [Related]
12. COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease.
Lee MS; Kim HS; Cho EK; Lim JH; Rinne JO
Neurology; 2002 Feb; 58(4):564-7. PubMed ID: 11865133
[TBL] [Abstract][Full Text] [Related]
13. New pharmacotherapy for Parkinson's disease.
Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
[TBL] [Abstract][Full Text] [Related]
14. Catechol-O-methyl transferase (COMT) inhibitors in patients with Parkinson's disease: is COMT genotype a useful indicator of clinical efficacy?
Rinne JO; Ulmanen I; Lee MS
Am J Pharmacogenomics; 2003; 3(1):11-5. PubMed ID: 12562212
[TBL] [Abstract][Full Text] [Related]
15. The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease.
Torkaman-Boutorabi A; Shahidi GA; Choopani S; Rezvani M; Pourkosary K; Golkar M; Zarrindast MR
Acta Neurobiol Exp (Wars); 2012; 72(3):272-82. PubMed ID: 23093014
[TBL] [Abstract][Full Text] [Related]
16. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.
Ceravolo R; Piccini P; Bailey DL; Jorga KM; Bryson H; Brooks DJ
Synapse; 2002 Mar; 43(3):201-7. PubMed ID: 11793426
[TBL] [Abstract][Full Text] [Related]
17. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
Kaakkola S
Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
[TBL] [Abstract][Full Text] [Related]
18. Association of Catechol-O-Methyltransferase Gene rs4680 Polymorphism and Levodopa Induced Dyskinesia in Parkinson's Disease: A Meta-Analysis and Systematic Review.
Dwivedi A; Dwivedi N; Kumar A; Singh VK; Pathak A; Chaurasia RN; Mishra VN; Mohanty S; Joshi D
J Geriatr Psychiatry Neurol; 2023 Mar; 36(2):98-106. PubMed ID: 35603896
[TBL] [Abstract][Full Text] [Related]
19. What is the impact of catechol-O-methyltransferase (COMT) on Parkinson's disease treatment?
Salamon A; Zádori D; Szpisjak L; Klivényi P; Vécsei L
Expert Opin Pharmacother; 2022 Jul; 23(10):1123-1128. PubMed ID: 35373688
[No Abstract] [Full Text] [Related]
20. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
Sampaio TF; Dos Santos EUD; de Lima GDC; Dos Anjos RSG; da Silva RC; Asano AGC; Asano NMJ; Crovella S; de Souza PRE
J Clin Pharmacol; 2018 Jul; 58(7):920-926. PubMed ID: 29578580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
